First CRISPR Cures (Casgevy Approval)
Gene editing transitions from the lab to human patients.
Casgevy became the first CRISPR-Cas9 based gene-editing therapy to receive regulatory approval (in the UK and by the US FDA) to cure Sickle Cell Disease and Beta Thalassemia.
Open in interactive timeline →Key Numbers
- Regulatory Status
- FDA Approved (2023)
- Mechanism
- In Vivo Gene Editing
Verified Facts
- The therapy works by extracting a patient’s stem cells, using CRISPR to edit the DNA so they produce fetal hemoglobin, and reinfusing them—effectively curing the genetic disease permanently.
- This marks the closing of the loop that started with the invention of CRISPR in 2012: humanity is now actively patching its own source code in clinical environments.
Frequently Asked Questions
What was First CRISPR Cures (Casgevy Approval)?
Casgevy became the first CRISPR-Cas9 based gene-editing therapy to receive regulatory approval (in the UK and by the US FDA) to cure Sickle Cell Disease and Beta Thalassemia.
When did First CRISPR Cures (Casgevy Approval) happen?
First CRISPR Cures (Casgevy Approval): Late 2023 - 2024 CE.
Why does First CRISPR Cures (Casgevy Approval) matter?
Gene editing transitions from the lab to human patients.
Sources & Further Reading
Cite This Page
AskHistoryAI. “First CRISPR Cures (Casgevy Approval).” AskHistoryAI — Interactive Timeline of Everything. Updated 2026-09-11. https://askhistoryai.com/event/tech-crispr-cures/
Every fact on this page is checked against the published fact ledger and methodology; sources are listed above.